Key Developments: Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

40.67USD
17 Apr 2014
Price Change (% chg)

$1.46 (+3.72%)
Prev Close
$39.21
Open
$39.45
Day's High
$42.53
Day's Low
$38.76
Volume
371,173
Avg. Vol
411,900
52-wk High
$49.79
52-wk Low
$15.77

Search Stocks

Latest Key Developments (Source: Significant Developments)

Agios Pharmaceuticals Inc initiates phase 1 study of AG-348
Thursday, 17 Apr 2014 08:00am EDT 

Agios Pharmaceuticals Inc:Announces dose administration of AG-348 in a phase 1 study in healthy volunteers.AG-348 is an orally available, potent, selective small molecule activator of pyruvate kinase-R (PK-R), a metabolic enzyme, which, when mutated, leads to pyruvate kinase (PK) deficiency, a rare, inherited hemolytic anemia.Phase 1, single-center, randomized, double-blind, placebo-controlled clinical trial will assess the safety and tolerability of AG-348 through dose escalation in healthy adult men and women.Key objectives of the trial include characterizing the safety, pharmacokinetic and pharmacodynamic relationships of AG-348 and select metabolic biomarkers.  Full Article

Agios Pharmaceuticals Inc exercises option to u.S. development and commercialization rights for IDH1 Program under Celgene Collaboration
Monday, 3 Feb 2014 08:00am EST 

Agios Pharmaceuticals Inc:Says it has elected to retain the United States development and commercial rights to the isocitrate dehydrogenase 1 (IDH1) program including the clinical candidate AG-120, in accordance with the terms of its global strategic collaboration with Celgene Corporation in the field of cancer metabolism.Says by exercising Agios' option to U.S. rights for the IDH1 program, Agios will lead development and commercialization activities for AG-120 in the U.S., and Celgene retains the option to lead development and commercialization activities for AG-120 in the rest of the world.Says Agios and Celgene are also collaborating on the development of AG-221.  Full Article

Agios Pharmaceuticals Inc Closes Initial Public Offering
Monday, 29 Jul 2013 05:00pm EDT 

Agios Pharmaceuticals Inc announced that the closing of its initial public offering of 6,772,221 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts, including 883,333 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount. J.P. Morgan and Goldman, Sachs & Co. acted as joint book-running managers for the offering. Cowen and Company and Leerink Swan acted as co-managers.  Full Article

Agios Pharmaceuticals Inc Prices Initial Public Offering
Tuesday, 23 Jul 2013 11:03pm EDT 

Agios Pharmaceuticals Inc announced the pricing of initial public offering of 5,888,888 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Agios. In addition, Agios has granted the underwriters a 30-day option to purchase up to 883,333 additional shares of common stock from Agios at the public offering price, less the underwriting discount. Agios' common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol AGIO on July 24, 2013. The offering is expected to close on July 29, 2013. J.P. Morgan and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Cowen and Company and Leerink Swan are acting as co-managers.  Full Article

Agios Pharmaceuticals Inc Unveils Estimated Terms Of IPO-DJ
Tuesday, 16 Jul 2013 05:38pm EDT 

Dow Jones reported that Agios Pharmaceuticals Inc planned Initial Public Offering (IPO) to raise funds to fund research and development of the Company's pipeline of early-stage cancer treatments. The Company expects to offer five million shares in an estimated range of $14 to $16 a share, according to a filing with the Securities and Exchange Commission. Agios last month filed plans to raise up to $86 million in common stock. On July 16, 2013, the Company said the IPO would raise net proceeds of about $67.5 million, assuming shares price at the midpoint of the estimated range. Celgene has agreed to purchase about $12.8 million of Agios shares in a separate private placement concurrent with the completion of the IPO, at a price equal to the public offering price.  Full Article

Agios Pharmaceuticals Inc Sees IPO Priced At $14-$16 Per Share-Form S-1
Thursday, 11 Jul 2013 08:00pm EDT 

Agios Pharmaceuticals Inc reported in its Form S-1 that it is offering 5,000,000 shares of its common stock. Common stock to be sold in the concurrent private placement to Celgene is 850,000 shares and Common stock to be outstanding after this offering and the concurrent private placement to Celgene is 29,380,339. This is the Company Initial Public Offering (IPO), and no public market currently exists for shares. The Company have applied to have common stock listed on The NASDAQ Global Market under the symbol 'AGIO.' The Company anticipate that the initial public offering price will be between $14.00 and $16.00 per share. the Company are an emerging growth company as that term is used in the Jumpstart Business Startups Act of 2012, and as such, have elected to comply with certain reduced public reporting requirements. The underwriters have an option for a period of 30 days to purchase up to 750,000 additional shares of our common stock. The Company intend to use the net proceeds from this offering and the concurrent private placement as follows: approximately $5 million to fund the costs of phase 1 clinical development of AG-221; if we exercise our option to develop and commercialize AG-120 in the United States, approximately $20-25 million to fund IND-enabling costs and our share of early development costs for AG-120; approximately $20 million to fund the IND-enabling activities and phase 1/2 clinical development of AG-348.  Full Article

Agios leukemia drug shows promise in tiny, early study

- An experimental drug being developed by Agios Pharmaceuticals Inc showed promising anti-cancer activity in a tiny Phase I study of patients with relapsed acute myeloid leukemia (AML), according to data presented on Sunday.

Search Stocks